Short-Course Antibiotic Therapy for Pediatric Community-Acquired Pneumonia: Evidence, Limitations, and the Need for Improved Diagnosis

1. Introduction

Community-acquired pneumonia (CAP) remains one of the most common infections in childhood. The availability of effective and safe antibiotics [1], advances in the prevention and treatment of viral infections [2], and widespread vaccination against Haemophilus influenzae type b [3] and Streptococcus pneumoniae [4] have substantially reduced its incidence and mortality. Nevertheless, CAP continues to be an important cause of pediatric morbidity, hospitalization, and death [5,6].

For decades, guidelines recommended antibiotic therapy for nearly all children diagnosed with CAP, regardless of the presumed etiology. In uncomplicated cases, treatment courses of 7–10 days—most commonly with amoxicillin—became standard practice [6]. This approach reflected the difficulty of reliably distinguishing bacterial from viral pneumonia in routine clinical settings, particularly in primary care, where microbiological testing is seldom available and clinical manifestations alone have limited ability to identify the cause. Consequently, clinicians generally favored antibiotic treatment, even when a viral etiology was suspected, accepting some overtreatment to reduce the risk of undertreating potentially severe bacterial infections.

Evidence that the emergence and spread of antimicrobial resistance (AMR) are driven by inappropriate and excessive antimicrobial use in human medicine, animal husbandry, and agriculture, as well as by prolonged antibiotic exposure [7,8], has led to the development of antimicrobial stewardship programs that include the use of shorter antibiotic courses. Optimizing treatment duration is now a cornerstone of antimicrobial stewardship, particularly as randomized clinical trials have shown that shorter courses are often non-inferior to longer regimens for many bacterial infections, while reducing unnecessary antimicrobial exposure and potentially limiting the selection of resistant organisms [9,10].

In children with CAP, 3–5 days of antibiotic therapy can achieve clinical outcomes comparable to those of conventional 7–10-day courses, thereby minimizing antibiotic exposure and the potential for resistance selection [5,11,12,13,14]. Because CAP accounts for a substantial proportion of antibiotic prescriptions in children, these findings have important implications for antimicrobial stewardship. Shorter courses have consequently been incorporated into recent consensus recommendations and clinical pathways for carefully selected children with uncomplicated CAP [15,16]. However, the strength of these recommendations remains influenced by limitations in the available evidence and by uncertainties regarding diagnosis, etiology, and antibiotic selection. Several limitations of the clinical trials supporting shorter treatment courses warrant consideration. This narrative review critically examines the findings of these studies.

2. Methods

A narrative literature review was conducted to examine evidence on antibiotic treatment duration for CAP in children, including the clinical evidence for shorter courses and the limitations that may affect its interpretation and application. Literature searches were performed in PubMed/MEDLINE, Google Scholar, and ClinicalTrials.gov for the period from 1 January 2010 to 30 September 2026. Relevant documents and guidance were also retrieved from the websites of international and national public health and regulatory authorities, including the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control, the European Medicines Agency, the US Food and Drug Administration, and national regulatory and surveillance agencies.

Search terms were used individually and in combination to identify publications addressing pediatric CAP, its etiology, and antibiotic treatment duration. Terms included “pneumonia,” “community-acquired pneumonia,” “child,” “children,” “adolescent,” “antibiotic therapy,” “duration,” “short-term,” “short course,” “safety,” “tolerability,” “etiology,” “virus,” “bacteria,” Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae. Additional publications were identified by manually screening the reference lists of relevant original studies, reviews, consensus statements, and public health guidance documents.

Priority was given to peer-reviewed original research, including randomized controlled trials, long-term follow-up studies, observational effectiveness studies, immunogenicity and safety studies, and human challenge studies. ClinicalTrials.gov records and guidance documents from relevant public health and regulatory authorities were also considered where they informed the review’s scope.

As this was a narrative review rather than a systematic review, study identification and selection did not follow a prespecified systematic-review protocol. No formal risk-of-bias assessment, quantitative evidence grading, or meta-analysis was performed. Findings were synthesized descriptively and interpreted in light of their biological plausibility, methodological robustness, clinical relevance, and implications for antibiotic treatment policy and practice.

3. Evidence Supporting Shorter Antibiotic Courses

The conclusion that shorter antibiotic courses can achieve clinical outcomes comparable to those of conventional 7–10-day regimens in children with community-acquired pneumonia (CAP) is supported by several systematic reviews and meta-analyses. A 2023 meta-analysis of 16 randomized trials involving 12,774 children treated as outpatients with oral antibiotics found no clinically meaningful differences between courses of ≤5 days and longer courses in clinical cure, treatment failure, relapse, hospitalization, mortality, or serious adverse events. The certainty of evidence for the main outcomes was moderate [17].

Similar findings were reported in a 2025 systematic review and meta-analysis of 17 studies involving 155,944 children, including 15 randomized trials. The analysis found no significant differences between short-course (≤6 days) and longer (>7 days) therapy in clinical cure, treatment failure, or overall adverse events. Shorter courses were also associated with fewer serious adverse events [18]. In addition, a systematic review of randomized trials found that a 3-day course of amoxicillin was non-inferior to longer regimens in young children with clinically diagnosed, non-severe CAP treated as outpatients, and was associated with fewer non-serious adverse events [19].

Key systematic reviews and randomized trials comparing shorter and conventional antibiotic regimens for pediatric CAP are summarized in Table 1.

4. Methodological Limitations of the Studies

The eligibility criteria used in studies comparing shorter with conventional antibiotic courses for pediatric CAP reveal several limitations that affect how their findings should be interpreted and applied. Most studies enrolled outpatients with presumed mild CAP diagnosed on clinical grounds, without radiological confirmation. Disease severity was generally assessed at enrollment, and laboratory investigations to determine etiology were rarely performed. As a result, it is difficult to establish which children had bacterial CAP or were likely to benefit from antibiotics. Nevertheless, all enrolled children received antibiotic treatment.

This approach should be considered in the context of clinical practice and existing guidance. Several international guidelines recommend antibiotic treatment for children diagnosed with CAP in outpatient settings [8,9]. More definitive diagnosis may require lung ultrasound or chest radiography, which may not be readily available in primary care; chest radiography also involves exposure to ionizing radiation. Similarly, tests to distinguish bacterial from viral infections or to stratify disease severity may be difficult to obtain, and many currently available investigations have limited diagnostic value.

At the same time, the lack of reliable tools to confirm CAP, identify bacterial causes, predict disease progression, and determine who is likely to benefit from antibiotics creates substantial diagnostic uncertainty. In practice, this uncertainty has contributed to a treatment approach that favors avoiding undertreatment, even though it can result in antibiotics being prescribed to children who may not need them. Thus, a proportion of antibiotic use in pediatric CAP may reflect the difficulty of making accurate diagnoses in routine clinical settings.

The evidence for shorter antibiotic courses should also be interpreted in light of this context. It does not establish that every case of pediatric CAP can be safely treated with an abbreviated regimen. Rather, the studies show that antibiotic exposure can be reduced in the populations enrolled, which may include children who would not have required antibiotic treatment. Shorter courses can therefore support antimicrobial stewardship by reducing antibiotic exposure, but they do not resolve the underlying question of which children with suspected CAP need antibiotics. More accurate diagnostic strategies are needed to identify those most likely to benefit from antibacterial therapy.

5. Limitations of Studies Evaluating Short-Course Therapy

5.1. Disease Diagnosis

In most studies evaluating short-course antibiotic therapy for CAP, diagnosis was based on clinical manifestations alone. Features commonly used to diagnose CAP—including fever, cough, tachypnea, respiratory distress, chest retractions, crackles, reduced breath sounds, and hypoxemia—are nonspecific and overlap substantially with those of other lower respiratory tract infections, such as bronchiolitis, viral-induced wheezing, and acute bronchitis, which typically do not benefit from antibiotics. Systematic reviews have found that neither individual symptoms nor combinations of clinical findings reliably distinguish CAP from other respiratory illnesses [19]. Consequently, some children enrolled in CAP trials may not have had CAP, resulting in diagnostic misclassification.

Several prognostic models have been developed to assess disease severity, including the Respiratory Index of Severity in Children (RISC), modified RISC (mRISC), RISC-Malawi, and PREPARE [20]. However, these tools were designed primarily to predict mortality, rather than to guide decisions about hospitalization, antibiotic duration, or eligibility for abbreviated therapy. RISC was derived in South African children with lower respiratory tract infections, mRISC in hospitalized Kenyan children, and RISC-Malawi in hospitalized Malawian children. PREPARE used multinational datasets from low- and middle-income countries to develop models for predicting in-hospital mortality [21,22,23,24,25]. Adult severity scores, such as CURB-65 and the Pneumonia Severity Index, were developed in adult populations and have not been adequately validated for routine use in pediatric CAP [27,28]. Thus, no severity score has demonstrated sufficient accuracy to reliably identify children who are suitable for abbreviated antibiotic regimens. Assessment of CAP severity continues to rely largely on clinical judgment and guideline-based criteria.

Factors such as respiratory distress, hypoxemia, inability to maintain hydration, altered mental status, complications, and the need for hospitalization are widely used to guide management [8,9]. However, these markers were not developed to determine optimal treatment duration. Their definitions vary across studies and guidelines, interobserver agreement is often suboptimal, and hospitalization decisions are influenced by multiple clinical and nonclinical factors.

A further limitation is the absence of etiological confirmation in most studies. Children with viral, bacterial, and mixed infections were generally analyzed together, in part because diagnostic methods are difficult to use or unavailable in outpatient settings. Multiplex respiratory PCR assays are highly sensitive but may not distinguish active infection from asymptomatic carriage or prolonged viral shedding [9,13]. Blood cultures are highly specific but have low sensitivity. Chest radiography can confirm the presence of pneumonia but provides limited information about its etiology, while inflammatory biomarkers, including C-reactive protein and procalcitonin, cannot reliably distinguish bacterial from viral infections [9,13,30,31,34].

This limitation is especially relevant because respiratory viruses are detected more often than bacterial pathogens in pediatric CAP, particularly among preschool-aged children. In the EPIC study, a pathogen was detected in 81% of children hospitalized with radiographically confirmed CAP. Viruses were identified in 66% of cases, pyogenic and atypical bacteria in 8% each, and viral–bacterial coinfections in 7% [30]. Juven et al. similarly detected viruses in 62% of hospitalized children with CAP, bacteria in 53%, and mixed viral–bacterial infections in 30% [32]. Studies of ambulatory children—the population represented in most short-course antibiotic trials—suggest an even greater predominance of viral pathogens, particularly among children younger than 5 years [31,33].

Taken together, these findings suggest that some children enrolled in trials of antibiotic duration may have had viral or mixed infections and may have derived little or no benefit from antibacterial therapy. If treatment effects are assessed without accounting for this etiological heterogeneity, outcomes among children who do not benefit from antibiotics may make cure rates appear higher and reduce observable differences between treatment groups. This may contribute to findings of non-inferiority for abbreviated regimens.

These diagnostic and population limitations affect how the apparent success of short-course regimens should be interpreted. Some enrolled children may not have had CAP, may have had non-bacterial CAP, or may have differed from children with severe or microbiologically confirmed bacterial pneumonia encountered in clinical practice. Because antibacterial therapy is indicated for bacterial CAP, including children without documented bacterial disease may have increased apparent cure rates, attenuated differences between treatment groups, and contributed to non-inferiority findings. The available evidence supports shorter courses for carefully selected children with clinically diagnosed mild CAP; however, it does not establish the efficacy of short-course therapy for confirmed bacterial CAP.

5.2. Antibiotic Treatment Regimens

Early studies of abbreviated therapy were conducted primarily in low- and middle-income countries. They enrolled children with WHO-defined non-severe pneumonia and compared different β-lactam agents, doses, and treatment durations, including 3- and 5-day courses of amoxicillin or cotrimoxazole [34,35]. More recent studies have generally standardized treatment to amoxicillin, although important differences remain. In the SAFER trial, outpatients with radiographically confirmed CAP received high-dose amoxicillin (75–100 mg/kg/day) for either 5 or 10 days; clinical cure rates were comparable between the groups [11]. The CAP-IT trial used a factorial design to evaluate treatment duration (3 vs. 7 days) and dosage (35–50 vs. 70–90 mg/kg/day) and found no significant differences in clinical outcomes across these regimens [12].

Interpreting these findings is further complicated by the relationship between the antibiotics studied and the bacterial causes of pediatric CAP. High-dose amoxicillin is active against susceptible Streptococcus pneumoniae, a principal bacterial target of current guidelines, but it is not active against other potential causes of CAP, such as Mycoplasma pneumoniae and Chlamydia pneumoniae. It may also be less reliable against β-lactamase-producing Haemophilus influenzae. None of the major treatment-duration trials stratified outcomes by microbiologically confirmed etiology. It therefore remains unclear whether abbreviated regimens are equally effective for bacterial CAP.

One possible explanation for the similar clinical outcomes observed across substantially different regimens is that many enrolled cases were viral and would have improved without antibacterial treatment. Alternatively, some bacterial infections may have resolved without active antimicrobial therapy. This may be relevant to infections caused by atypical bacteria, including M. pneumoniae, a substantial proportion of which are reported to be self-limiting and to resolve without specific antimicrobial treatment.

Several features of the duration trials limit the interpretation and generalizability of their findings (Table 2).

6. Conclusions

Taken together, the evidence suggests that shorter antibiotic courses can be used for selected children with uncomplicated CAP. Reducing treatment duration is a practical way to limit antibiotic exposure among children who are prescribed antibiotics, but it does not address whether antibiotics are needed in the first place. Greater reductions in antibiotic use will likely depend on improving the diagnosis of CAP and identifying its etiology more accurately.

Lung ultrasound (LUS) is a promising diagnostic tool because it is rapid, radiation-free, relatively inexpensive, and available at the point of care. Systematic reviews and meta-analyses have reported high diagnostic accuracy, with sensitivity and specificity frequently exceeding 90% and performance that often matches or surpasses chest radiography. LUS can detect small subpleural consolidations, pleural effusions, and dynamic air bronchograms that may be missed on radiographs, leading investigators to propose it as a first-line imaging tool for pediatric CAP [36]. Evidence in outpatient populations has added support: in a study of 246 ambulatory children with suspected CAP who underwent both LUS and computed tomography, LUS had higher sensitivity than chest radiography (91.3% vs. 75.0%), with comparable specificity and predictive values [37]. Other prospective studies have found associations between ultrasound findings, disease severity, and clinical outcomes, suggesting that LUS may also help with risk stratification and follow-up [38].

However, LUS cannot reliably determine the cause of pneumonia. Sonographic findings overlap across etiologies, and no ultrasound feature can establish the etiology in an individual patient [39]. Findings therefore need to be interpreted alongside clinical, laboratory, and microbiological information. Point-of-care C-reactive protein (CRP) and procalcitonin (PCT) are potential adjuncts because they can be relatively inexpensive and provide results quickly from small-volume blood samples [40]. PCT has shown greater ability than CRP to distinguish typical bacterial CAP from other causes [41]. In the EPIC study, children with microbiologically confirmed typical bacterial pneumonia had substantially higher PCT concentrations than those with viral or atypical infections. No child with PCT below 0.1 ng/mL had evidence of typical bacterial infection, and concentrations below 0.25 ng/mL were associated with a 96% negative predictive value for typical bacterial CAP [42]. Diagnostic approaches may help identify pneumonia and refine etiological assessment, although each has important limitations (Table 3).

Microbiological testing may further inform clinical decisions. Rapid antigen or molecular assays for influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 are increasingly available in outpatient pediatric settings and can return actionable results within minutes. Studies combining LUS with other diagnostic tools, particularly PCT, have reported improved diagnostic performance and the potential to reduce unnecessary imaging and antibiotic exposure [43,44,45]. However, most studies have involved hospitalized or critically ill patients, assessed diagnostic accuracy rather than antibiotic stewardship outcomes, or have not established thresholds validated for ambulatory children. The effect of integrated LUS, biomarker, antigen, and molecular testing strategies on outpatient antibiotic prescribing therefore remains uncertain. Large prospective studies in ambulatory children are needed to determine whether these approaches can improve prescribing and clarify the role of shorter antibiotic courses in pediatric CAP.